Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Although not the most prevalent comorbid condition in patients with T2DM, heart failure was the most fatal in a 17-year long nationwide real-life cohort study.
Read More »Heart Failure in T2DM: Ready for Prime Time?
Optimal Treatment In T2D For CV Protection
How triple therapy can lead to optimal cardiovascular and renal protection.
Read More »Role of Magnesium in Type 2 Diabetes and Stroke
Adequate amounts of magnesium in the diet could reduce the risk of type 2 and cerebral vascular incidents.
Read More »Associations between Prediabetes and Vascular Complications
Do patients with prediabetes share the same vascular complication risk seen in patients with T2D?
Read More »The VERTIS CV Study – SGLT-2 Inhibitors’ Cardiovascular and Renal Outcomes in T2D
This article is part of a live interview with Dr. Engel, Associate Vice President, Cardiometabolic and Women's Health, Merck Research Laboratories.
Read More »Elevated HbA1c = CVD
The study aimed to investigate whether testing HbA1c will improve cardiovascular disease risk assessment.
Read More »Live Longer and Cardiovascular Disease-Free
How many years can semaglutide add to your life?
Read More »The Long-term Cardiovascular Effects of Ertugliflozin in Type 2 Diabetes
Does Ertugliflozin share the same cardiovascular and renal benefits recently demonstrated by other SGLT-2 Inhibitors?
Read More »SGLT-2 vs. GLP-1: Cardiovascular Outcomes in Adults with Type 2 Diabetes
Cardiovascular events decline for patients using which antidiabetic medication?
Read More »Dulaglutide Provides CVD Protection with or without Metformin
Data from the REWIND trial suggest that dulaglutide has cardioprotective properties.
Read More »